{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056292","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.253996+00:00","generated_at":"2026-06-02T07:16:03.882365+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NewAmsterdam Pharma Q1 net loss $93.8M; Phase 3 readouts on track for 2024","bullets":["Enrolled over 9,500 patients in Phase 3 PREVAIL CVOT; topline data from BROOKLYN in Q3 2024 and BROADWAY in Q4 2024.","Cash position $481.1M at March 31, vs $340.5M Dec 31, bolstered by $190M public offering.","Net loss $93.8M ($1.06/diluted share) vs $42.0M ($0.51) year ago; revenue fell to $1.4M from $8.6M.","Dosed first patients in TANDEM (fixed-dose obicetrapib/ezetimibe); topline expected Q1 2025.","Appointed William H. Lewis as Board Chair and Juliette Audet as Chief Business Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056292","json":"https://secwatch.observer/filing/0000950170-24-056292.json","markdown":"https://secwatch.observer/filing/0000950170-24-056292.md","text":"https://secwatch.observer/filing/0000950170-24-056292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024056292/0000950170-24-056292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024056292/nams-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:16:03.882365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c77ef2bb295eb1b35b735bba4b2b575b430d6bc","claim":"NewAmsterdam Pharma Co N.V. reported financial results for quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release announcing corporate updates and its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024056292/0000950170-24-056292-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}